In this exclusive video from the GUILD Conference 2020, Edward V. Loftus Jr., MD, professor of medicine in the division of gastroenterology and hepatology at the Mayo Clinic in Rochester, Minnesota, discusses his presentation on some of the important updates in Crohn’s disease in 2019.
“What we tried to do was identify either papers or abstracts within the last year or so that we thought would be worth delving into,” Loftus told Healio Gastroenterology and Liver Disease.
In the review, Loftus and his co-presenter, Miguel Rigueiro, MD, of Cleveland Clinic, discussed a number of topics, including NUDT15 as a cause for thiopurine-induced myelosuppression, the SERENE-CD study and post-operative infection with anti-TNF as seen in the PUCCINI trial.
“In this prospective study, there was absolutely no signal for increased complications, including surgical site infections in patients who had recently been on an anti-TNF,” Loftus said. “These were very reassuring data. This is the only prospective study thus far, so I think it goes a long way to reassuring our surgical colleagues that perioperative use of anti-TNF isn’t the culprit. The culprit is probably the underlying disease severity.”
Loftus E, Regueiro M. Crohn’s Disease: The Year in Review. Presented at: GUILD Conference 2020; February 16-19, 2020; Maui, Hawaii.
Disclosure: Loftus reports consulting for AbbVie, Allergan, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Gilead, Janssen, Pfizer, Takeda and UCB Pharma; and research support from AbbVie, Amgen, Celgene, Genentech, Gilead, Janssen, MedImmune, Pfizer, Robarts Clinical Trials, Seres Therapeutics, Takeda, and UCB Pharma.